BTAI - Schizophrenia Player BioXcel's Drug Faces Funding Headwinds Analyst Downgrades Stock | Benzinga
Truist downgraded BioXcel Therapeutics Inc (NASDAQ: BTAI) from Buy to Hold, citing significant near-term funding and clinical development headwinds.
Wednesday, the company updated recent developments with its late-stage clinical programs and patent portfolio for Igalmi (dexmedetomidine) sublingual film, including the scheduled FDA meeting to discuss the TRANQUILITY and SERENITY III programs.
The analyst writes that the cash runway is a significant risk. Truist said it would be more confident in ...